Risk-Benefit Profile for Raloxifene: 4-Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk-Benefit Profile for Raloxifene: 4-Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial

Published:2004-04-12 Issue:8 Volume:19 Page:1270-1275
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Barrett-Connor Elizabeth,Cauley Jane A,Kulkarni Pandurang M,Sashegyi Andreas,Cox David A,Geiger Mary Jane

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference28 articles.

1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial;Writing Group for the Women's Health Initiative Investigators;JAMA,2002

2. Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative;Freedman;Control Clin Trials,1996

3. Estrogen plus progestin and the risk of coronary heart disease;Manson;N Engl J Med,2003

4. Postmenopausal hormone replacement therapy: Scientific review;Nelson;JAMA,2002

5. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial;Ettinger;JAMA,1999

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials;BMJ;2023-05-02

2. Medical optimization of osteoporosis for adult spinal deformity surgery: a state-of-the-art evidence-based review of current pharmacotherapy;Spine Deformity;2022-12-01

3. Pros and Cons of Skeletal Medications in the COVID-19 Era;Current Treatment Options in Rheumatology;2022-07-16

4. Endocrine prevention of breast cancer;Molecular and Cellular Endocrinology;2021-06

5. Breast cancer chemoprevention: An update on current practice and opportunities for primary care physicians;Preventive Medicine;2019-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3